Previous results have indicated that valsartan administration at bedtime as opposed to upon wakening improves the day/night ratio of blood pressure (BP) (nocturnal decline of BP relative to the diurnal mean) towards a more dipper pattern without loss in 24-hour efficacy [Hypertension. 2003;42:283-290]. Some studies have found differential effects of antihypertensive drugs according to the dipping status of the patients. Accordingly, we investigated the administration time-dependent antihypertensive efficacy of valsartan in non-dipper patients. We studied 190 non-dipper patients with grade 1-2 essential hypertension (72 men), 53.9Ϯ13.2 years of age, randomly assigned to receive single daily valsartan monotherapy (160 mg/day) either upon awakening or at bedtime. BP was measured by ambulatory monitoring at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 hours before and after 3 months of therapy. Physical activity was simultaneously monitored every minute by wrist actigraphy to accurately calculate the diurnal and nocturnal means of BP on a per subject basis. The highly significant BP reduction after 3 months of treatment with valsartan (PϽ0.001) was slightly larger after bedtime dosing of valsartan (13.0 and 8.1 mm Hg reduction in the 24-hour mean of systolic and diastolic BP after valsartan on awakening; 15.2 and 10.6 mm Hg when valsartan was administered at bedtime). The day/night ratio was unchanged after valsartan on awakening (0.4 and 0.7 for systolic and diastolic BP; PϾ0.309). This ratio was significantly increased (7.2 and 7.1 for systolic and diastolic BP, PϽ0.001) when valsartan was administered at bedtime, which resulted in 75% of the patients reverted to dippers, a significant increase in the percentage of patients with controlled BP after treatment, and a significant reduction in urinary albumin excretion. Independently of dosing time, 160 mg/day valsartan monotherapy efficiently reduces BP for the entire 24 hours of the day. In hypertensive patients who are non-dippers at baseline, dosing time with valsartan should be chosen at bedtime, for increased efficacy during nocturnal resting hours, improved renal function, and the potential associated reduction in cardiovascular risk.
P-149 ADMINISTRATION TIME-DEPENDENT EFFECTS OF AMLODIPINE ON AMBULATORY BLOOD PRESSURE IN PATIENTS WITH ESSENTIAL HYPERTENSION
Amlodipine, a calcium antagonist of the 1,4-dihydropyridine type, has been shown to be effective in reducing blood pressure (BP) throughout the day and night when given once daily. However, the potential chronopharmacologic differing effects on BP of amlodipine have only been addressed occasionally. We investigated the administration-time dependent antihypertensive efficacy of amlodipine in patients with essential hypertension. We studied 194 patients with grade 1-2 essential hypertension (101 men and 93 women), 55.3Ϯ12.1 years of age, randomly assigned to receive a single daily dose of amlodipine (5 mg/day) either upon awakening or at bedtime. BP was measured by ambulatory monitoring at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 hours before and after 3 months of therapy.
Physical activity was simultaneously monitored every minute by wrist actigraphy to accurately calculate the diurnal and nocturnal means of BP on a per subject basis. The BP reduction after 12 weeks of therapy with amlodipine was slightly but not significantly larger after bedtime dosing (10.4 and 7.3 mm Hg reduction in the 24-hour mean of systolic and diastolic BP after amlodipine on awakening; 11.5 and 7.0 mm Hg after bedtime dosing; PϾ0.463 for treatment-time effect). This BP reduction was similar during both daytime activity and nighttime resting hours, independently of dosing time, indicating a full 24-hour therapeutic coverage of amlodipine administered either on awakening or at bedtime. The day/night BP ratio (calculated as the nocturnal decline of BP relative to the diurnal mean) was slightly reduced for diastolic BP after morning treatment (-1.6, Pϭ0.037), but remained unchanged after bedtime dosing of amlodipine (increase of 0.2 and 0.7 in systolic and diastolic BP, PϾ0.337).
Results from this trial demonstrate that amlodipine efficiently reduces BP for the entire 24 hours of the day independently of the time of its administration with respect to the rest-activity cycle of each individual patient. The similar BP reduction observed for the diurnal and nocturnal BP means indicates that amlodipine does not modify the circadian pattern of BP variability, even if administered at bedtime.
Key Words: Amlodipine, Chronotherapy, Circadian Previous results have indicated that valsartan dosed at bedtime as opposed to upon wakening improves the day/night ratio of blood pressure (BP) towards a more dipper pattern without loss in 24-hour efficacy [Hypertension. 2003; 42:283-290] . Urinary albumin excretion (UAE) in non-dippers has been shown to be significantly greater than in dippers [Am J Hypertens. 1994; 7:23-29] . Moreover, the reduction of UAE provides renal protection and reduces cardiovascular risk [Lancet. 2001; 357: 1601 -1608 . We hypothesized that improving the day/night BP ratio could further reduce UAE in hypertensive patients. We studied 123 previously untreated non-proteinuric patients with grade 1-2 essential hypertension (50 men and 73 women), 51.0Ϯ11.4 years of age, randomly assigned to receive valsartan (160 mg/d) as a monotherapy either upon awakening or at bedtime. BP was measured by ambulatory monitoring at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours before and after 3 months of therapy. The patients collected their urine during the first 24 hours of ambulatory monitoring. Physical activity was simultaneously monitored every minute by wrist actigraphy to accurately calculate the diurnal and nocturnal means of BP on a per subject basis. The significant BP reduction after 3 months of valsartan was similar for both treatment times (13.9 and 9.1 mm Hg reduction in the 24-hour mean of systolic and diastolic BP after valsartan on awakening; 15.2 and 10.3 mm Hg after valsartan at bedtime). The day/night BP ratio was unchanged after valsartan on awakening, but significantly increased by 5.4% when valsartan was administered before bedtime. UAE was significantly reduced, mainly after bedtime treatment (31% reduction). This reduction was independent of the 24-hour BP decrease, but highly correlated with the decrease of nocturnal BP (rϭ0.326, Pϭ0.007) and with the increase in day/night BP ratio, mainly after bedtime treatment (rϭ0.395, Pϭ0.002). Bedtime valsartan administration improves the day/night BP ratio to a more dipper profile This results in further decrease of UAE as compared to morning dosing, and could thus reduce cardiovascular risk, a hypothesis that deserves further prospective investigation.
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